SARTORIUS AG, DE0007165631

SARTORIUS AG / DE0007165631

01.07.2025 - 17:30:24

Sartorius completes acquisition of MatTek

SARTORIUS AG / Key word(s): Mergers & Acquisitions
(news with additional features)

01.07.2025 / 17:30 CET/CEST
The issuer is solely responsible for the content of this announcement.


Göttingen, Germany | July 1, 2025



The life science group Sartorius has successfully closed the acquisition of MatTek Corp, including Visikol Inc, from the Swedish BICO Group AB, as announced in April. The acquisition was completed on July 1, 2025, following the receipt of the required regulatory approval and the fulfillment of other customary closing conditions. With the integration of the business into its Lab Products and Services division, Sartorius is expanding its cell technology portfolio and creating synergies with existing solutions for drug development, including cell analysis instruments, reagents, and AI models.
 
MatTek is a leading developer and manufacturer of human cell-based microtissues and 3D models that accelerate drug development. The advanced cell models mimic the structure and function of human tissue and deliver more accurate, cost-effective, and reproducible results compared to traditional 2D cell cultures, while reducing the need for animal testing. The company employs more than 80 people at its headquarters in Ashland, Massachusetts, USA, and at its production site in Bratislava, Slovakia.


A profile of Sartorius
Sartorius is a leading international partner of life sciences research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group’s Lab Products & Services Division focuses on laboratories performing research and quality control at pharmaceutical and biopharmaceutical companies as well as academic research institutes. The Bioprocess Solutions Division, with its broad product portfolio focusing on single-use solutions, helps customers manufacture biotech medications, vaccines, and cell and gene therapies more safely, rapidly, and sustainably. The company, based in Göttingen, Germany, has a strong global reach with around 60 production and sales sites worldwide. Sartorius regularly expands its portfolio through the acquisition of complementary technologies. In 2024, the company generated sales revenue of around 3.4 billion euros. Around 13,500 employees are working for customers around the globe. 

Visit our Newsroom and follow Sartorius on LinkedIn.


Contact
Leona Malorny
Head of External Communications
+49 551 308 4067
leona.malorny@sartorius.com

Additional features:

File: | Media Release


01.07.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

Language: English
Company: SARTORIUS AG
Otto-Brenner-Straße 20
37079 Göttingen
Germany
Phone: +49.(0)551-308.0
Fax: +49.(0)551-308.3289
E-mail: info@sartorius.com
Internet: www.sartorius.com
ISIN: DE0007165631, DE0007165607
WKN: 716563, 716560
Indices: DAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard), Hanover; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 2162694

 
End of News EQS News Service

2162694  01.07.2025 CET/CEST
@ dgap.de